Agenus (NASDAQ:AGEN), Inc. (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.
Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform. Its adjuvant portfolio features QS-21 Stimulon, an immunostimulatory component used to bolster vaccine efficacy. Through strategic collaborations and licensing agreements with leading pharmaceutical companies, the firm has advanced multiple programs into late-stage clinical trials, focusing on refractory and treatment-resistant cancer indications.
Founded in 1994 as Antigenics and rebranded as Agenus in 2016, the company operates research and development activities in the United States and Europe. In 2015, it completed the spin-out of NewLink Genetics, enabling a streamlined focus on its oncology-centric assets. Over the years, Agenus has expanded its scientific platform through targeted acquisitions and partnerships, reinforcing its commitment to innovative immunotherapeutic strategies.
Under the leadership of founder and Chief Executive Officer Garo Armen, Agenus continues to build on its legacy of immuno-oncology innovation. The company is dedicated to translating its platform technologies into combination therapies that address unmet needs in cancer treatment, with the goal of delivering durable responses and improving patient outcomes worldwide.
